Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.

Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.

<p>Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.</p>

Сохранить в:

Библиографические подробности
Главный автор:	Seyed Reza Mousavi (13223324) (author)
Другие авторы:	Alihasan Rahmani (22676321) (author), Maryam Amini Pouya (22676324) (author), Elnaz Zabihi Eidgahi (22676327) (author), Mohamad Delirrad (22676330) (author), Hamed Hosseini (3480455) (author), Alireza Ghassemi Toussi (22676333) (author), Behnaz Hedayatjoo (22676336) (author), Seyyedeh Maryam Afshani (22676339) (author), Mohammad Amin Ghobadi (22676342) (author), Mohammad Reza Shahidi (22676345) (author), Seyed Amirhossein Mousavi (22676348) (author), Maryam Barghbani (22676351) (author), Mahdi Jannati Yazdan Abad (22676354) (author)
Опубликовано:	2025
Предметы:	Medicine Cell Biology Neuroscience Physiology Pharmacology Biotechnology Immunology Science Policy Mental Health patients received either day monitoring period total antivenom consumption treating snakebite envenomation antivenom units administered razi antivenom group snakebite envenomation razi antivenom razi group antivenom infusion 49 units 40 units snafab antivenom razi antivenoms snafab group serum sickness recovery rate primary endpoint muscle weakness mean number may 15th april 17th anaphylactic shock adverse events 98 %). 92 ). 27 ). 100 percent
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.
по: Seyed Reza Mousavi (13223324)
Опубликовано: (2025)

The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
по: Seyed Reza Mousavi (13223324)
Опубликовано: (2025)

Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].
по: Seyed Reza Mousavi (13223324)
Опубликовано: (2025)

Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.
по: Seyed Reza Mousavi (13223324)
Опубликовано: (2025)

Size exclusion chromatography (SEC) analysis of the three antivenoms and control proteins.
по: Rebecca J. Edge (12732488)
Опубликовано: (2025)

SVMP activity of <i>E. ocellatus s. str.</i> and <i>E. romani</i> venoms and their neutralisation by the three different antivenoms.
по: Rebecca J. Edge (12732488)
Опубликовано: (2025)

Plasma clotting activity of <i>E. ocellatus s. str.</i> and <i>E. romani</i> venoms and their neutralisation by the three different antivenoms.
по: Rebecca J. Edge (12732488)
Опубликовано: (2025)

PLA<sub>2</sub> activity of <i>E. ocellatus s. str.</i> and <i>E. romani</i> venoms and their neutralisation by the three different antivenoms.
по: Rebecca J. Edge (12732488)
Опубликовано: (2025)

The titre of three antivenoms against <i>E. ocellatus s. str.</i> and <i>E. romani</i> venoms determined by end-point titration ELISA.
по: Rebecca J. Edge (12732488)
Опубликовано: (2025)

Antivenom efficacy against <i>E. romani</i> (Nigeria) in a murine pre-incubation model. The efficacy of EchiTAbG, SAIMR Echis and Echiven against <i><i>E. romani</i></i> (Nigeria) reported as ED<sub>50</sub> (µL), potency (mg/mL) and volume of antivenom per mg of venom (µL/mg)<i>.</i> 95% confidence intervals indicated in parentheses.
по: Rebecca J. Edge (12732488)
Опубликовано: (2025)

An overview of the antivenoms used in this study. The table shows manufacturer information, batch/lot numbers and expiry dates, composition of antivenom immunoglobulins, protein concentration, and the venom reported to be used in immunisation and their geographical origin (where known) as indicated on the inserts of the products. Asterisk indicates assumed <i><i>E. ocellatus sensu lato.</i></i> ^ Although stated as <i><i>E. carinatus</i></i> in the product insert, this now refers to <i><i>E. pyramidum</i></i> due to taxonomic changes.
по: Rebecca J. Edge (12732488)
Опубликовано: (2025)

Histopathological changes in the skin after administration of <i>M. l. obtusa</i> (MLO) venom, a venom antivenom mixture, and antivenom injected locally following venom exposure.
по: Gevorg Avagyan (22601121)
Опубликовано: (2025)

Antivenom availability and reported challenges in snakebite case management among healthcare professionals in Afar Region, Ethiopia.
по: Abebe M. Aga (22655919)
Опубликовано: (2025)

Dermal lesions induced by <i>M. l. obtusa</i> (MLO) venom are inhibited by ovine-derived experimental antivenom.
по: Gevorg Avagyan (22601121)
Опубликовано: (2025)

Histopathological changes in the spleen after injection of <i>M. l. obtusa</i> (MLO) venom and venom/antivenom mixture.
по: Gevorg Avagyan (22601121)
Опубликовано: (2025)

ED<sub>100</sub> survival times.
по: Rebecca J. Edge (12732488)
Опубликовано: (2025)

Maximum likelihood phylogeny of the <i>Echis ocellatus</i> group inferred from 1433 base pairs of mitochondrial CYTB and NADH4 sequence.
по: Rebecca J. Edge (12732488)
Опубликовано: (2025)

PLA<sub>2</sub> assay optimisation.
по: Rebecca J. Edge (12732488)
Опубликовано: (2025)

Preclinical assays survival times.
по: Rebecca J. Edge (12732488)
Опубликовано: (2025)

Plasma clotting assay raw data.
по: Rebecca J. Edge (12732488)
Опубликовано: (2025)

SVMP assay raw data.
по: Rebecca J. Edge (12732488)
Опубликовано: (2025)

PLA2 assay raw data.
по: Rebecca J. Edge (12732488)
Опубликовано: (2025)

ELISA raw data.
по: Rebecca J. Edge (12732488)
Опубликовано: (2025)

BCA assay raw data.
по: Rebecca J. Edge (12732488)
Опубликовано: (2025)

APTT, PT and INR levels after the intravenous administration of PBS (Control), Venom and Antivenom + Venom (AnV + V) (experimental repeats–6, mean ± SEM; one-way ANOVA with Dunnett’s multiple comparison test).
по: Gevorg Avagyan (22601121)
Опубликовано: (2025)

RBC, HGB, HCT levels after the intravenous administration of PBS (Control), Venom and Antivenom + Venom (AnV + V) (experimental repeats–6, mean ± SEM; one-way ANOVA with Dunnett’s multiple comparison test, p* < 0.05; p*** < 0.001; p**** < 0.0001).
по: Gevorg Avagyan (22601121)
Опубликовано: (2025)

Post-discharge follow-up practices and estimates of snakebite severity.
по: Abebe M. Aga (22655919)
Опубликовано: (2025)

Professional distribution and experience of healthcare providers involved in snakebite management in the study hospitals.
по: Abebe M. Aga (22655919)
Опубликовано: (2025)

Training status, training needs, and confidence levels in snakebite management among healthcare professionals.
по: Abebe M. Aga (22655919)
Опубликовано: (2025)

Cross-tabulation of healthcare professionals’ snakebite awareness and training status by profession, with corresponding p-values.
по: Abebe M. Aga (22655919)
Опубликовано: (2025)

Case screening approaches, first-line treatment practices, and estimated frequency of snakebite case presentations among healthcare professionals.
по: Abebe M. Aga (22655919)
Опубликовано: (2025)

Tissue damage in Spleen and Skin: + (mild), ++ (moderate), +++ (severe).
по: Gevorg Avagyan (22601121)
Опубликовано: (2025)

Complete Blood Count (CBC) Parameters Across Experimental Groups (experimental repeats–6, mean ± SEM; one-way ANOVA with Dunnett’s multiple comparison test).
по: Gevorg Avagyan (22601121)
Опубликовано: (2025)

Coagulation assay raw data by group and animal.
по: Gevorg Avagyan (22601121)
Опубликовано: (2025)

Complete blood count (CBC) raw data organized by group and animal.
по: Gevorg Avagyan (22601121)
Опубликовано: (2025)

Crotalidae polyvalent immune Fab (ovine) dosing in <i>Agkistrodon contortrix</i> envenomation: a single-center retrospective cohort study
по: Kevin Baumgartner (14075764)
Опубликовано: (2025)

Distribution of number of antivenom doses administered to patients (n = 87).
по: Jean-Philippe Chippaux (790696)
Опубликовано: (2025)

<b>Strategic Point Coverage for Scorpion Accident Care: Methodological Considerations and Application in São Paulo State, Brazil</b>Santos P
по: Gabriella Pereira dos Santos (22054562)
Опубликовано: (2025)

<b>Supplementary Material – </b> <b>Thiophene-triazole hybrids inhibit the major toxic activities </b><b>of </b><b><i>Bothrops jararacussu</i></b><b> venom</b>
по: Brenda Bairral de Oliveira (22447117)
Опубликовано: (2025)

<b>Supplementary Material – Thiophene-triazole hybrids inhibit the major toxic activities </b><b>of </b><b><i>Bothrops jararacussu</i></b><b> venom</b>
по: Brenda Bairral de Oliveira (22447117)
Опубликовано: (2025)